News for I-Mab (IMAB)

Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs)

I-Mab Chairman plans $2 million ADS purchase

I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.

PR NewswireROCKVILLE, MD, Jan. 6, 2025 Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024

I-Mab Biopharma (IMAB) reports Q3 2024 results with GAAP EPS of -$0.11, missing by $0.04.

- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.

Givastomig shows promise in gastric cancer study

I-Mab reveals Phase 1 data for lung cancer treatment

I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit.

Announcement of Board and Management Changes I-Mab today announced its changes in the board of directors and the management team. Mr. Shuai Chen has been... | April 3, 2023

Read Stock Analysts’ Price Target Changes for May 27th (ACHL, ADEVF, ANPCY, ATDRY, ATGSY, AVDL, BKKVF, BMEA, BNDSF, BNTGY) at ETF Daily News

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 1) Abbott ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7) ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 5) Curis, ...